NovoCure Limited (NVCR)
25.58
0.20 (0.79%)
At close: Jan 28, 2025, 1:46 PM
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.
The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NovoCure Limited
| Country | JE |
| IPO Date | Oct 1, 2015 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,453 |
| CEO | Ashley Cordova |
Contact Details
Address: No. 4 The Forum Saint Helier, JE | |
| Website | https://www.novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Ashley Cordova | Chief Executive Officer |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Prof. Yoram Palti M.D., Ph.D. | Founder & Chief Technology Officer |
| Barak Ben Arye | General Counsel |
| Frank Leonard | Executive Vice President & President of Novocure Oncology |
| Ingrid Goldberg | Vice President of Investor Relations |
| Michael Puri | Chief Human Resources Officer |
| Uri Weinberg M.D., Ph.D. | Chief Innovation Officer |
| William F. Doyle | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 15, 2025 | 4 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 3 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Dec 17, 2024 | 8-K/A | [Amend] Current Report |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |